Internal tandem duplications of the Flt3 gene (Flt3/ITDs) are present in about 18% of all AML cases and are therefore one of the most frequent somatic gene mutations in AML. Little is known about the role of Flt3/ITDs in leukemogenesis or their clinical relevance. In this study we compared 18 samples with Flt3/ITDs and 63 AML samples without these mutations with respect to clinical prognosis, cytokine responsiveness, progenitor cell content and repopulation in the NOD/SCID mouse. We found that in patients with a mutation CR rates are reduced (P = 0.03) and relapse rates are increased (P = 0.01), indicating the prognostic importance of Flt3/ITDs. This is also emphasized by the finding that in patients under the age of 60 years, as well as in older patients the event-free survival was more unfavorable for the mutant patients (P = 0.003 and P = 0.03, respectively). At diagnosis Flt3/ITD and non-mutant AML bone marrow samples did not differ in their progenitor/stem cell frequencies. Cobblestone area forming cell (CAFC) subsets showed a similar frequency distribution in mutant and nonmutant samples. In 7-day liquid cultures, Flt3/ITD samples showed a reduced growth in response to a variety of myeloid growth factors. In contrast, Flt3/ITD samples displayed a higher ability to engraft the NOD/SCID bone marrow with leukemic cells. Together these data show that the Flt3/ITD represents an important diagnostic marker for patient prognosis, and that the presence of these mutations is associated with altered proliferative ability of progenitors in vivo and in vitro. Leukemia (2000) 14, 675-683.
Introduction
The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) or fetal liver tyrosine kinase-2 (FLK-2), [1] [2] [3] [4] belongs to the group of class III receptor tyrosine kinases (RTKs) which also include the receptors c-kit and c-fms. Signals generated by ligand-induced dimerization of these receptors involve tyrosine phosphorylation of certain regions of the receptor and activation of cellular tyrosine kinases. Whilst a large proportion of acute myeloid leukemias (AML) has been found to express class III RTKs [5] [6] [7] [8] their potential role in leukemia is still unclear. Flt3 ligand (Flt31) and Flt3 are both expressed on precursor-B ALL and AML cells, [9] [10] [11] [12] as well as on normal progenitor cells. [13] [14] [15] [16] In 17-20% of AML patients in the Japanese 17 and west-European 18 population, as well as in patients with leukemic transformation of myelodysplasia, 19 internal tandem duplications (ITDs) have been reported in the part of the Flt3 gene coding for the juxtamembrane (JM) through first tyrosine kinase (TK-1) domains of the protein. These types of mutations have not been found in acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML), blast crisis CML, nor have they been reported in cells of normal individuals. In ALL, Flt3/ITDs have only been reported in two patients which at closer examination were considered to be biphenotypic leukemia. 20 Though Flt3/ITDs are also observed in childhood AML their frequency is significantly lower when compared to adult AML. Frequencies reported for the Japanese childhood AML population vary between 11% (Kondo et al, seven out of 64 cases studied) 21 and 5.3% (Iwai et al, five out of 94 cases studied). 22 A possible explanation for the observed lower incidence in childhood AML could be that Flt3/ITDs results from genomic instability as was postulated by the latter authors. Kiyoi et al 23 have shown that in COS cells, transduced with cDNA encoding for Flt3/ITDs, elongation of the JM domain and ligandindependent dimerization of the mutant receptor occurs, thus resulting in a constitutive activation. This effect was seen in both mutant/mutant and in mutant/wildtype dimers of the receptor.
Immunoprecipitation studies of those mutant receptors showed evidence for a conformational change in the Cterminal region of the mutant receptor.
Recently we have shown 18 that in comparison to nonmutant AML cells, cells with Flt3/ITDs have a reduced proliferative ability in stroma-supported cultures. This effect could not be abrogated by the addition of cytokines to these cultures. We have now investigated whether the presence of Flt3/ITDs in AML cases within the adult population correlated with (1) their short-term proliferative response to single cytokine stimulation; (2) the ability of these cells to engraft in the bone marrow of immunodeficient mice (NOD/SCID) [24] [25] [26] and (3) the frequency of leukemic progenitor and stem cells, as measured by a leukemic cobblestone area forming cell assay (L-CAFC).
27,28 Furthermore, we have analyzed whether the presence of Flt3/ITDs in AML in the Dutch population of patients predicts prognosis, as was recently published for the Japanese population.
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Materials and methods
Patient samples
Diagnosis bone marrow samples of patients with AML were obtained after informed consent. Cases were classified according to the French-American-British (FAB) committee recommendations. 30 Mononuclear cells were isolated by Ficoll separation followed by T cell depletion, typically resulting in a population containing over 95% blasts. After isolation, cells were subjected to controlled freezing and stored in liquid nitrogen. Before use cells were thawed by stepwise dilution in Iscove's modified Dulbecco's medium (IMDM, Gibco, Breda, The Netherlands) containing 1% BSA. After thawing viability varied between 70 and 90% as assessed by dye exclusion.
After diagnosis patients were treated according to studies of the adult Dutch-Belgian Hemato-Oncology Group, HOVON. 33 protocols. Six patients received palliative treatment only and were therefore excluded from the survival analysis. In these protocols induction therapy included an anthracyclin and cytarabine and in patients less than 60 years allogeneic and autologous stem cell transplantation or intensive chemotherapy for consolidation were applied as postremission therapy. In the Hovon-29 study induction therapy consisted of Ara-C (200 mg/m 2 ) for 7 days combined for the last 3 days with idarubicin (12 mg/m 2 ) (cycle I) followed by a second cycle consisting of Ara-C (6 days, 1000 mg/m 
Stratification according to karyotype-risk groups
As cytogenetic aberrations are thought to be one of the most important prognostic factors for AML 34, 35 patients were stratified in three groups, ie a good-risk group consisting of patients defined by a karyotype of t(8;21), t(15;17) or inv(16); a poorrisk group defined by del(5), del(7), or deletions of the q-arms of these chromosomes, t (6, 9) , alterations in the 11q23 region or the presence of multiple aberrations (more than 3) in the karyotype. All other karyotypic aberrations and the normal karyotype were included in an intermediate-risk group.
Determination of Flt3 mutants
All AML samples were analyzed for mutations in exons 11 and/or 12 of the Flt3 gene by using a modified PCR procedure as described elsewhere. 17 The use of exon 11 and 12 specific primers allowed us to cover the whole JM and the first part of the TK-1 domain where most of the reported mutations are located. Genomic DNA was prepared using a standard procedure. 36 Briefly, DNA from about 10 4 cells was amplified in a total of 50 l reaction mixture, containing single strength PCR buffer, 10 pM of each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Supertaq, SpheroQ, Leiden, The Netherlands). Preheating of the samples at 95°C was followed by amplification for 35 cycles consisting of: 1 min at 43°C, 1 min at 72°C, 1 min at 95°C. Following these cycles a final extension at 72°C was performed for 10 min. PCR products were stained with SYBR green I (Molecular Probes, Leiden, The Netherlands) and resolved on 3% agarose gel. As confirmation, samples positive for a Flt3-mutation were re-analyzed in a second PCR using the primers 11F and 12R.
Sequencing of patient samples with a mutated Flt3 gene
If both PCR reactions using the 11F/11R and 11F/12R combinations resulted in an abnormal PCR product, this was purified from the gel using a JETsorb kit (Genomed, Bad Oeyenhausen, Germany). This purified PCR product was subjected to a second PCR using fluorescent ddNTPs after which sequencing was carried out using an automated DNA sequencing system (ABIPRISM 310 genetic analyzer, Perkin Elmer Applied Biosystems, Foster City, CA, USA).
Short-term proliferative response to single cytokine stimulation
To determine the proliferative response of AML samples to single cytokine stimulation we used a thymidine incorporation assay. As monocytes are known to produce many cytokines and thus potentially may perturb the results, we removed these cells prior to their use in culture by adhesion to plastic (1 h incubation at 37°C in alpha-MEM (Gibco) +1% BSA (Sigma, St Louis, MO, USA). The non-adherent cells were plated in 96-well plates at a density of 2 × 10 4 cells/well in serum-free medium 37 and cultured for 6 days. The cytokines used were either hIL-3 (25 ng/ml, Genetics Institute, Cambridge, MA, USA), hGM-CSF (10 ng/ml, Immunex, Seattle, WA, USA), hG-CSF (100 ng/ml, Amgen, Thousand Oaks, CA, USA), hM-CSF (100 U/ml, Genetics Institute) or hSCF (100 ng/ml, Amgen). After 6 days the cells were incubated overnight with 0.1 Ci tritiated-thymidine (Amersham, Buckinghamshire, UK) per well and harvested on to nitrocellulose filters. Thymidine incorporation was determined using a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden) as counts per minute (c.p.m.). All cultures were done in triplicate.
The stimulation index was calculated by dividing the mean c.p.m. of the triplicate cultures and the mean c.p.m. of a 30 Gy irradiated control of the sample.
Leukemic cobblestone area forming cell assay
The cobblestone area forming cell assay was performed as described. 38 Briefly, confluent FBMD-1 stromal layers in 96-well plates (Costar, Cambridge, MA, USA) were overlaid with AML cells in a limiting dilution setup. The cells were cultured in medium consisting of IMDM (Gibco) supplemented with 10% heat-inactivated fetal calf serum (Summit Biotechnology, Fort Collins, CO, USA), 5% horse serum (Gibco), ␤-mercaptoethanol (5 × 10 −5 mol/l) and hydrocortisone-21-hemisuccinate (10 −6 mol/l, Sigma). rhII-3 (8 ng/ml) and rhG-CSF (20 ng/ml) (both a generous gift of the Genetics Institute) were added to the medium and all cultures were performed at 37°C and 10% CO 2 in a humidified atmosphere.
Input values were equivalent to 1 × 10 5 nucleated cells/well and 12 dilutions three-fold apart were used for each sample with 15 replicates per dilution. The percentage of cells wells with at least one phase-dark clone (cobblestone area, consisting of at least five cells) beneath the stromal layer was determined weekly and leukemic CAFC (L-CAFC) frequencies were calculated using Poisson statistics. 39 Based on evidence from murine correlation studies, it is assumed that both normal and leukemic cobblestone areas that are observed late in culture are indicators of primitive long-term repopulating cell in vivo, whilst early appearing clones are indicators of transiently repopulating and less primitive cells.
The NOD/SCID mouse model
Among a variety of immunodeficient mouse strains, we and others have evaluated that nonobese diabetic (NOD)/LtSz scid/scid strain appears to be most useful in allowing the engraftment of human AML progenitors. 40, 41 In contrast to the CB17/SCID strain, which is only defective in B and T cell function, this strain is characterized by an additional functional deficit in NK cell function as well as defective antigenpresenting cells and an absence of circulating complement.
NOD/SCID mice were bred in the Erasmus animal facility and housed under specified pathogen-free conditions, using laminar air flow units. Mice were supplied with sterilized food and acidified tap water to which 100 mg/l ciprofloxacine (Bayer AG, Leverkusen, Germany) was added. Both food and drink were available ad libitum. Before transplantation of the AML cells the mice received a total body irradiation of 3.5 Gy gamma radiation ( 137 Cs source, Gammacell, Atomic Energy of Canada, Ottawa, Canada). Transplantation of the AML cells was done by injecting 3 × 10 7 AML cells in the lateral tail vein. After 30 days the mice were killed by CO 2 inhalation in accordance with the institutional animal research regulations. Cell supsensions were made from both femora and used for flow cytometry.
Flow cytometry
To determine the percentage of AML cells in bone marrow cell suspensions from mice that had been transplanted, cells were stained with antibodies against the human common leukocyte antigen (CD45), CD34, CD33 and CD38 (CD45-FITC, CD38-FITC, CD33-PE and CD34-APC, all obtained from Coulter Immunotech, Marseille, France) and measured using a FACScalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Analysis was done using the Cell Quest software package (Becton Dickinson). Erythrocytes were excluded from analysis by gating on forward and perpendicular light scatter whilst dead cells were excluded by staining with 7-amino-actinomycin D (7-AAD, Molecular Probes, Eugene, OR, USA). Human cells were considered to have engrafted when the percentage of CD45-positive cells in the mouse bone marrow was at least 0.5%. Because, in contrast to human umbilical cord blood cells, almost all samples expressed over 90% CD33 either in combination or absence of CD38 we considered them to be of leukemic origin. The only samples not abundantly expressing CD33 were the AML-M0 samples which, after passage in NOD/SCID, could be characterized by a high expression of CD34 (50-100%).
Statistical analysis
Statistical analysis of the data was performed using the SPSS software package (SPSS Inc, Chicago IL, USA). Significance of differences for the proliferation, L-CAFC and SCID assays was determined by the non-parametrical Mann-Whitney U test. The Fisher's exact test for 2 × 2 tables was used to evaluate complete remission (CR) and relapse rates. For the survival analysis the Kaplan-Meier method of the same software packLeukemia age was used. The Breslow test was used to check for equality of the survival distributions. Overall survival was calculated from date of diagnosis to date of (leukemia-related) death. The leukemia-free survival (LFS) was calculated from date of diagnosis to date of relapse or death. Patients not achieving CR were scored as having an LFS of 0.01. Patients dying from non-leukemia related causes during first CR were included until date of death. In all evaluations, values were considered significant if P values were below 0.05.
Results
Characterization of patients
A total of 81 diagnosis samples (bone marrow) from patients with AML were screened for the presence of a Flt3 mutation. Of the samples 18 patients (22%) were found to have such a mutation.
All Flt3/ITD mutations found were in the exon 11 region of the gene whilst none were found in exon 12. However, sequence analysis showed an involvement of one or more amino acids of exon 12 in two of the exon 11 mutant samples (see below). As previously shown 18,42 the mutation was randomly distributed over the FAB classes while no correlation with any known cytogenetic aberration was observed. In most of the Flt3/ITD positive patients the mutation was present as a heterozygous mutation but in four cases the ITD appeared as a single abberant band on gel, indicating the presence of either as a homozygous mutation or, more likely, a hemizygous deletion of the wild-type gene.
The characteristics of 18 AML patients with the mutation and 63 AML patients without such a mutation included in this study are shown in Table 1 .
Sequence analysis of the Flt3 mutant samples (Table 2 ) showed tandem duplications varying in length from 10 to 35 amino acids (30-105 bp). All mutations were restricted to the JM domain of the receptor. All ITDs included the duplication of at least one putative SH2 binding motif (YFYV and/or YEYDLK). Four patients additionally showed mutations in the amino acid (AA) sequence. These mutations were either in the starting or terminal AA of the duplicated sequence. The mutation in patient 1 was ending with a mutation of the last two AA, ie tyrosine and aspartate to serine and proline, respectively. The mutation in patient number 7 was valine to leucine, in patient 15 lysine to threonine, and in patient number 16 phenylalanine to leucine. Two patients showed an involvement of the first (patient 14) or first and second (patient 12) AA of exon number 12
Clinical response and prognosis of AML patients with and without Flt3/ITD
All 70 patients of whom we were able to obtain therapy response data were evaluated for their initial therapy response. From Table 1 , it can be deduced that the CR rate of 8/17 (47.1%) patients in the population with Flt3/ITD was significantly reduced when compared to that of 39/49 (79.6%) patients in the population without Flt3/ITDs (P = 0.03). At a median follow-up period of 23 months in the group without ITDs, 10 of the 39 (25.6%) patients who had achieved CR had relapsed, whilst six out of eight (75.0%) patients with ITDs had relapsed (P = 0.01).
The overall survival (OS) curves (Figure 1a ) and leukemia- free survival (LFS) curves (Figure 1b) clearly suggest a significant reduction in CR rate and prognosis by the presence of Flt3/ITD in AML (P = 0.002 for OS and 0.001) for LFS). Details for the LFS of the mutant population are shown in Table 3 . As we are aware that a bias can be introduced by comparing the total heterogeneous AML population, we also looked at the LFS for the two largest sub-populations that could be distinguished within our dataset, ie patients with de novo AML ( Figure 1c ) and patients with an intermediate-risk karyotype (Figure 1d ). In both cases the differences still remained significant (P = 0.004 and P = 0.008, respectively). As also age is known to be an important prognostic factor we divided the samples in two groups according to age (Figure 2) . In both the age group of under 60 years ( Figure 2a ) and over 60 years ( Figure 2b ) the differences between the Flt3/ITD and non-mutant group with respect to LFS remained significant (P = 0.003 and 0.03, respectively).
Short-term proliferative response of AML
We have recently shown 18 that the presence of Flt3/ITDs in AML reduces the proliferative ability of AML in stroma-supported cultures. As this was a rather unexpected finding in the light of the poor prognosis of this type of AML, we investigated whether this reduced proliferative response could also be seen in short-term cultures (7 days) without stromal support ( Figure  3) . We used single cytokines with a well-defined proliferative effect on the myeloid compartment of the bone marrow. As depicted by the large numbers of outlayers in both the Flt3 mutant and non-mutant samples of the de novo AML group, the cytokine response in this population is very heterogeneous. However, in almost all cases, the Flt3/ITD positive samples showed a decreased response to cytokines. Statistical analysis revealed that for the combined AML population (Figure 3a 
Frequency analysis of AML progenitors using the L-CAFC assay
In an attempt to investigate whether the L-CAFC content of AML with Flt3/ITDs differed from samples without such a mutation, we analyzed a panel of 27 AML-samples (10 with Flt3/ITDs and 17 without Flt3/ITD). Irrespective of the presence or absence of Flt3/ITDs we did not observe significant differences in CAFC frequencies in the AML bone marrow when the samples were subdivided on the basis of FAB classification, cytogenetics or hematological background (data not shown). As shown in Figure 4 there is no difference in the frequency of the CAFC-subsets (week types) between mutant and non-mutant samples. Both Flt3 mutant and non-mutant samples showed a decreased frequency of the later (ie more primitive) CAFC subsets as compared to the week 1-2 frequencies. This is in contrast to the frequency of the various CAFC subsets in normal human bone marrow and mobilized peripheral blood, which are about similar. 38 Not clear from Figure 4 is that there is a large heterogeneity in the CAFC frequencies of the various AML samples. This is especially prominent at the early weeks after overlay (eg at week 2 the highest observed frequency was 4791 CAFC/10 5 cells whilst the lowest was 0.32 CAFC/10 5 cells). This heterogeneity could not be correlated with any specific subgroup of AML (ie FAB class, cytogenetics or hematological background).
Outgrowth of AML cells in the NOD/SCID mouse
The NOD/SCID mouse model was used to investigate the in vivo leukemia-initiating capacity of both Flt3/ITD positive and negative AML. Due to the large number of cells needed for a reproducible engraftment (3 × 10 7 cells/mouse) and the limited availability of animals we were only able to analyze a limited number of samples. Groups of three mice/sample were injected with AML cells and analyzed at day 30 after transplantation. We were unable to analyze samples of FAB class M3 as all samples of this type injected into NOD/SCID resulted in death of the mice within 24 h after injection, with the highest mortality within 1 h. This was most probably due to in vivo lysis of the cells.
Analysis of the percentage of engraftment in the total AML population (Figure 5a ) pointed to an increased ability of the Flt3/ITD samples to repopulate the NOD/SCID mouse bone marrow (P = 0.01). This difference could also be observed Leukemia when selecting the samples on basis of FAB classification (Figure 5b ). Whilst the non-mutant samples of the M2 and M5 type showed the lowest median repopulation of all samples investigated, the Flt3/ITD mutant samples of these FAB types showed a marked increase in human chimerism. Furthermore, this Figure also indicates great variability between the FAB classes where in the non-mutant population the M0 samples gave rise to the highest median level of chimerism. The most variable responses with both low and high repopulating samples was observed in the M4 FAB class. Though only a limited number (n = 4) of Flt3-mutant samples could be analyzed, we conclude that the increased outgrowth in the NOD/SCID mice is indeed related to the presence of Flt3/ITDs as this effect can also be observed when arranging the samples according to cytogenetics (Figure 5c ) or previous hematological history (Figure 5d ).
Discussion
Our current study clearly demonstrates that AML patients who present with a Flt3/ITD mutation at diagnosis have a signifi- cantly poorer prognosis when compared to patients without such a mutation. This effect on the survival of AML patients is also evident in the elderly patients (Ͼ60 years) or in patients without any known cytogenetic aberrations. Our study on the Dutch population therefore confirms and extends the recent report on the clinical impact of Flt3/ITDs in the Japanese Leukemia population. 29 However, in contrast to this study we found a significant reduction in the remission rate in the Flt3/ITD mutant population.
In our previous report, 18 we have shown that Flt3/ITD mutant AML has a reduced proliferative ability in long-term stroma-supported cultures when compared to non-mutant samples. This aberrant characteristic behavior is also observed in short-term cultures as described here. The short-term proliferation of Flt3/ITD samples is lower (though not always significant) when compared to non-mutant samples and independent of cytokines used. In contrast, Lö wenberg et al 43 have shown that a higher autonomous in vitro proliferation of AML correlates with a poorer prognosis. A similar, though less significant, correlation was also observed in cytokine-stimulated cultures. 44 It therefore seems opportune to re-evaluate a large group of AML samples, that exclude patients carrying a Flt3/ITD mutation, with respect to growth factor response and patient prognosis.
The decreased proliferation of the mutant samples is not reflected in the L-CAFC assay as all CAFC subset frequencies in the L-CAFC analysis are similar in both mutant and nonmutant populations. We also observed no differences in size of the cobblestone areas derived from either Flt3/ITD mutant or non-mutant CAFC.
Though the number of AML progenitors thus does not seem to differ between mutant and non-mutant populations we observed that the Flt3/ITD population had a better ability to engraft the bone marrow of NOD/SCID mice. One explanation for this might be that these mice provided a microenvironment, which more closely mimicked the human (in vivo) situation than did the ex vivo cultures, and favored outgrowth of the mutant samples. Another possible explanation might be that the mutation in the Flt3 gene causes an aberrant activation of the receptor resulting in an inhibited apoptosis 9 leading to a higher surviving fraction, which is able to repopulate the mouse. Actual proof of which mechanisms are involved in the aberrant behavior of AML with Flt3/ITD will require an in-depth molecular characterization of both the wild-type and mutant Flt3.
In the light of the observed aberrant proliferative ability of Flt3/ITD AML it would be extremely interesting to re-evaluate current prognostic parameters based on exclusion of the Flt3/ITD samples.
In conclusion, our clinical data suggest that prognosis is strongly related to the presence of Flt3/ITDs. We therefore regard patients with Flt3/ITDs to belong to a distinct AML subpopulation that seems to poorly respond to current treatment protocols and thus should have risk stratification with treatment tailored to their prognostic factors.
